Compare Stocks

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GDRX GoodRx	$6.73 +3.5%	$6.89	$4.14 ▼ $9.37	$2.66B	1.42	1.56 million shs	591,168 shs
HCM HUTCHMED	$16.36 -0.5%	$15.99	$10.68 ▼ $20.73	$2.85B	0.81	123,798 shs	187,961 shs
LIFW MSP Recovery	$0.83 -12.0%	$0.95	$0.65 ▼ $21.50	$115.28M	-2.01	2.05 million shs	432,200 shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GDRX GoodRx	+3.54%	-2.75%	+2.75%	+4.67%	+15.44%
HCM HUTCHMED	-0.55%	-9.56%	-4.27%	+14.65%	-2.68%
LIFW MSP Recovery	-11.98%	-29.65%	+9.22%	-31.40%	-95.85%

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GDRX GoodRx	3.2388 of 5 stars	4.2	0.0	1.7	1.7	1.9
HCM HUTCHMED	1.4619 of 5 stars	3.4	2.0	3.3	0.0	0.6
LIFW MSP Recovery	1.4891 of 5 stars	0.0	5.0	3.0	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GDRX GoodRx	2.47	Hold	$8.78	30.43% Upside
HCM HUTCHMED	2.75	Moderate Buy	$29.70	81.54% Upside
LIFW MSP Recovery	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest LIFW, GDRX, and HCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2024	GDRX GoodRx	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Weight ➝ Overweight	$9.00
3/25/2024	GDRX GoodRx	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$7.50 ➝ $10.00
3/1/2024	GDRX GoodRx	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $7.50
3/1/2024	GDRX GoodRx	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$5.00 ➝ $8.00
3/1/2024	GDRX GoodRx	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$7.00 ➝ $8.00
3/1/2024	GDRX GoodRx	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$6.50 ➝ $7.50
3/1/2024	GDRX GoodRx	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$12.00 ➝ $14.00
3/1/2024	GDRX GoodRx	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$7.50 ➝ $8.00
3/1/2024	GDRX GoodRx	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$8.00 ➝ $9.00
3/1/2024	GDRX GoodRx	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$7.00 ➝ $10.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GDRX GoodRx	$750.27M	3.54	$0.43 per share	15.79	$1.93 per share	3.49
HCM HUTCHMED	$838M	3.40	$0.61 per share	26.67	$4.27 per share	3.83
LIFW MSP Recovery	$7.70M	14.97	$2.59 per share	0.32	$16.95 per share	0.05

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GDRX GoodRx	-$8.87M	-$0.02	N/A	21.71	3.57	-1.18%	2.45%	1.25%	5/9/2024 (Confirmed)
HCM HUTCHMED	$100.78M	N/A	0.00	34.08	N/A	N/A	N/A	N/A	5/22/2024 (Estimated)
LIFW MSP Recovery	-$7.42M	N/A	0.00	∞	N/A	-268.17%	-19.47%	-10.90%	7/15/2024 (Estimated)

Latest LIFW, GDRX, and HCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/9/2024	N/A	GDRX GoodRx	$0.0870	N/A	-$0.0870	N/A	N/A	N/A
2/29/2024	Q4 2023	GDRX GoodRx	$0.02	$0.02	N/A	$0.10	$195.59 million	$196.64 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GDRX GoodRx	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
LIFW MSP Recovery	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GDRX GoodRx	0.85	7.12	7.12
HCM HUTCHMED	0.06	2.72	2.60
LIFW MSP Recovery	0.39	0.54	0.54

Ownership

Institutional Ownership

Company	Institutional Ownership
GDRX GoodRx	63.77%
HCM HUTCHMED	8.82%
LIFW MSP Recovery	3.77%

Insider Ownership

Company	Insider Ownership
GDRX GoodRx	1.37%
HCM HUTCHMED	3.60%
LIFW MSP Recovery	19.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
GDRX GoodRx	694	395.00 million	389.59 million	Optionable
HCM HUTCHMED	1,988	174.25 million	167.98 million	Not Optionable
LIFW MSP Recovery	100	138.87 million	111.93 million	Optionable

LIFW, GDRX, and HCM Headlines

Source	Headline
	UPDATE: LifeWallet Announces a Comprehensive Settlement with a Group of Affiliated Property & Casualty Insurers globenewswire.com - April 18 at 8:42 PM
	LifeWallet Announces a Comprehensive Settlement with 10 Affiliated Property & Casualty Insurers, Doing Business in 15 States globenewswire.com - April 18 at 6:06 PM
	MSP Recovery (NASDAQ:LIFW) Shares Up 1.2% americanbankingnews.com - April 18 at 2:54 AM
	MSP Recovery (NASDAQ:LIFW) Trading 1.2% Higher americanbankingnews.com - April 18 at 2:18 AM
	Trump Mastered The Art of the SPAC Deal. Cashing Out Is Harder finance.yahoo.com - April 16 at 3:00 PM
	LIFW Stock Earnings: MSP Recovery Reported Results for Q4 2023 msn.com - April 15 at 1:18 PM
	LifeWallet Announces Fiscal Year and Fourth Quarter 2023 Financial Results globenewswire.com - April 15 at 6:55 AM
	Financial Survey: MSP Recovery (NASDAQ:LIFW) & JOYY (NASDAQ:YY) americanbankingnews.com - April 14 at 1:18 AM
	MSP Recovery, Inc. (NASDAQ:LIFW) Sees Large Decline in Short Interest marketbeat.com - April 12 at 2:50 PM
	MSP Recovery: AI-Powered Healthcare Claims Recoveries Plagued By Multiple Red Flags seekingalpha.com - April 12 at 4:27 AM
	Wanda Agrees to Sell James Bond’s Yachtmaker Sunseeker to Lionheart finance.yahoo.com - April 10 at 4:12 PM
	Unusually High Volume Points to Upside in These Stocks marketbeat.com - April 5 at 7:46 AM
	Unusually High Volume Points to Upside in These Stocks (LIFW) marketbeat.com - April 5 at 7:45 AM
	Wall Street Breakfast: Oh Boy! seekingalpha.com - April 3 at 8:06 AM
	MSP Murdo Fraser's legal threat to police over 'hate incident' bbc.co.uk - April 3 at 3:06 AM
	Palantir (NYSE:PLTR) Reveals Stake in MSP Recovery, Sending LIFW Soaring msn.com - April 2 at 5:04 PM
	Palantir Technologies reports 6.5% in MSP Recovery msn.com - April 2 at 7:45 AM
	Cano Health sells shares of MSP Recovery for over $35k investing.com - March 31 at 2:04 PM
	MSP Recovery, Inc. (NASDAQ:LIFW) Major Shareholder Sells $17,454.50 in Stock insidertrades.com - March 31 at 6:12 AM
	MSP Recovery, Inc. (NASDAQ:LIFW) Major Shareholder Cano Health, Inc. Sells 24,935 Shares marketbeat.com - March 29 at 6:48 PM
	MSP Recovery (NASDAQ:LIFW) Shares Down 3.8% on Insider Selling marketbeat.com - March 28 at 12:23 AM
	Cano Health, Inc. Sells 23,600 Shares of MSP Recovery, Inc. (NASDAQ:LIFW) Stock insidertrades.com - March 26 at 9:18 PM
	Cano Health, Inc. Sells 23,600 Shares of MSP Recovery, Inc. (NASDAQ:LIFW) Stock marketbeat.com - March 26 at 9:18 PM
	Insider Selling: MSP Recovery, Inc. (NASDAQ:LIFW) Major Shareholder Sells 46,246 Shares of Stock insidertrades.com - March 21 at 7:57 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

GoodRx

NASDAQ:GDRX

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

HUTCHMED

NASDAQ:HCM

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

MSP Recovery

NASDAQ:LIFW

MSP Recovery, Inc., doing business as LifeWallet, operates as a healthcare recoveries and data analytics company in the United States and Puerto Rico. The company offers claims recovery services, including services to related parties or third parties to assist entities with pursuit of claims recovery rights. It is also developing LifeWallet, a platform for real-time analytics at the point of care which helps in identifying the primary insurer and assisting providers in receiving customary rates for accident-related treatment. MSP Recovery, Inc. was founded in 2014 and is headquartered in Coral Gables, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial